Loading...
New Strategies for Treatment of ALK Rearranged Non-Small Cell Lung Cancers
The identification of oncogenic alterations in subsets of non-small cell lung cancers (NSCLC) is transforming clinical care. Genomic rearrangements in the anaplastic lymphoma kinase (ALK) are detected in 3 to 7% of NSCLC patients. The ALK tyrosine kinase inhibitor crizotinib has demonstrated clinica...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3477548/ https://ncbi.nlm.nih.gov/pubmed/22010214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1404 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|